Amy Mcbride Wendell Purchases 1,475 Shares of Solventum (NYSE:SOLV) Stock

Solventum Corporation (NYSE:SOLV) Director Amy Mcbride Wendell purchased 1,475 shares of the stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Solventum Stock Down 2.4%

Shares of NYSE SOLV opened at $66.00 on Friday. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $88.20. The stock has a 50-day moving average price of $76.64 and a two-hundred day moving average price of $76.01. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The company has a market cap of $11.45 billion, a price-to-earnings ratio of 7.44, a PEG ratio of 1.11 and a beta of 0.40.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has approved a stock repurchase plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. UBS Group reissued a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Finally, Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Hilltop National Bank raised its position in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. CrossGen Wealth LLC bought a new position in Solventum during the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum in the 3rd quarter valued at about $25,000. Deseret Mutual Benefit Administrators raised its stake in shares of Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after acquiring an additional 163 shares in the last quarter. Finally, JNBA Financial Advisors raised its holdings in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.